IGF2BP3 and urinary bladder cancer: CCK-8 detection results showed that after cisplatin treatment, the sensitivity of bladder cancer cells in the IGF2BP3 knockdown group was significantly increased (Figure 4A), while overexpression of IGF2BP3 significantly decreased the sensitivity of bladder cancer cells to cisplatin (Figure 4B).